HILS vs. AIMD, LIXT, PCSA, KA, YMTX, XBIO, PTIX, KTRA, HOTH, and SHPH
Should you be buying Hillstream BioPharma stock or one of its competitors? The main competitors of Hillstream BioPharma include Ainos (AIMD), Lixte Biotechnology (LIXT), Processa Pharmaceuticals (PCSA), Kineta (KA), Yumanity Therapeutics (YMTX), Xenetic Biosciences (XBIO), Protagenic Therapeutics (PTIX), Kintara Therapeutics (KTRA), Hoth Therapeutics (HOTH), and Shuttle Pharmaceuticals (SHPH). These companies are all part of the "pharmaceutical preparations" industry.
Hillstream BioPharma (NASDAQ:HILS) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, community ranking, media sentiment, valuation and risk.
Hillstream BioPharma has a beta of 3.08, suggesting that its share price is 208% more volatile than the S&P 500. Comparatively, Ainos has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.
In the previous week, Ainos had 1 more articles in the media than Hillstream BioPharma. MarketBeat recorded 1 mentions for Ainos and 0 mentions for Hillstream BioPharma. Ainos' average media sentiment score of 0.38 beat Hillstream BioPharma's score of 0.00 indicating that Ainos is being referred to more favorably in the news media.
Hillstream BioPharma has a net margin of 0.00% compared to Ainos' net margin of -11,205.49%. Ainos' return on equity of -47.96% beat Hillstream BioPharma's return on equity.
Hillstream BioPharma received 1 more outperform votes than Ainos when rated by MarketBeat users.
13.4% of Hillstream BioPharma shares are owned by institutional investors. 30.2% of Hillstream BioPharma shares are owned by company insiders. Comparatively, 4.6% of Ainos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Hillstream BioPharma has higher earnings, but lower revenue than Ainos. Hillstream BioPharma is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.
Summary
Hillstream BioPharma beats Ainos on 7 of the 13 factors compared between the two stocks.
Get Hillstream BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HILS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HILS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hillstream BioPharma Competitors List
Related Companies and Tools
